Reliability and validity of the CMT neuropathy score as a measure of disability
- 12 April 2005
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 64 (7), 1209-1214
- https://doi.org/10.1212/01.wnl.0000156517.00615.a3
Abstract
Objective: To determine the validity and reliability of the Charcot-Marie-Tooth disease (CMT) neuropathy score (CMTNS) in patients with inherited neuropathy. Background: Natural history studies and potential treatment trials for patients with various forms of CMT are limited by the lack of quantitative methodologies to monitor disease progression. Most cases of CMT can be considered length-dependent axonal neuropathies because disability for even the demyelinating forms correlates with length-dependent axonal degeneration. The total neuropathy score (TNS) is a validated composite measure of disability in length-dependent axonal neuropathies but is weighted toward predominantly sensory neuropathies. Thus, the authors have devised a CMTNS, modified from the TNS, to provide a single measure to quantify CMT disability. Methods: The authors measured inter- and intrainvestigator reliability of the CMTNS and performed a validation of the score with the Neuropathy Impairment Score (NIS), patient self-assessment scores, an ambulation index, and other measures of disability. Results: Inter- and intrainvestigator reliability was more than 95% in the 60 patients evaluated. Patients could be divided into mild (CMTNS, ≤10), moderate (CMTNS, 11 to 20), and severe (CMTNS, ≥21) categories and demonstrated excellent correlations among all measures of disability. Conclusion: The Charcot-Marie-Tooth disease (CMT) neuropathy score is a validated measure of length-dependent axonal and demyelinating CMT disability and can be investigated as an end point for longitudinal studies and clinical trials of CMT.Keywords
This publication has 14 references indexed in Scilit:
- Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth diseaseNature Medicine, 2004
- Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A)Nature Medicine, 2003
- Hereditary motor and sensory neuropathies: a biological perspectiveThe Lancet Neurology, 2002
- Use of the Multiple Sclerosis Functional Composite as an Outcome Measure in a Phase 3 Clinical TrialArchives of Neurology, 2001
- Variables influencing neuropathic endpointsNeurology, 1995
- Genetic aspects of hereditary motor and sensory neuropathy (types I and II)Journal of Medical Genetics, 1980
- Distal and scapuloperoneal distributions of muscle involvement occurring within a family with type I hereditary motor and sensory neuropathyZeitschrift für Neurologie, 1980
- Genetic and clinical aspects of Charcot‐Marie‐Tooth's diseaseClinical Genetics, 1974
- Lower Motor and Primary Sensory Neuron Diseases With Peroneal Muscular AtrophyArchives of Neurology, 1968
- Lower Motor and Primary Sensory Neuron Diseases With Peroneal Muscular AtrophyArchives of Neurology, 1968